10-K: OptiNose, Inc. Reports Annual Results; Faces Going Concern Uncertainty Amid Merger Agreement with Paratek

OptiNose, Inc. reports its annual results, highlighting XHANCE commercialization efforts and a pending merger with Paratek Pharmaceuticals, while acknowledging substantial doubt about its ability to continue as a going concern.

Summary

• OptiNose, Inc., a specialty pharmaceutical company, has released its Form 10-K filing for the fiscal year ended December 31, 2024.
• The company's primary focus is the commercialization of XHANCE, a nasal spray for the treatment of chronic rhinosinusitis with and without nasal polyps.
• In March 2024, the FDA approved XHANCE for the treatment of chronic rhinosinusitis without nasal polyps.
• The company is relaunching XHANCE to focus on the larger market opportunity created by the new indication.
• Net product revenues from XHANCE sales were $78.2 million in 2024, compared to $71.0 million in 2023.
• The average net revenue per prescription from XHANCE sales was $285 in 2024, a 36% increase from $209 in 2023.
• The company is required to conduct clinical trials of XHANCE in adolescent patients with chronic rhinosinusitis with and without nasal polyps.
• OptiNose has identified conditions and events that raise substantial doubt about its ability to continue as a going concern.
• The company's continuation as a going concern is dependent on its ability to maintain compliance with financial covenants under the A&R Note Purchase Agreement, generate sufficient cash flows, and/or obtain additional capital.
• On March 19, 2025, OptiNose entered into a merger agreement with Paratek Pharmaceuticals, Inc., with the merger expected to close in the second or third quarter of 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as increased revenue and FDA approval, the going concern uncertainty and potential covenant breaches weigh heavily on the overall outlook.

Positives

• XHANCE net product revenues increased to $78.2 million in 2024 from $71.0 million in 2023.
• Average net revenue per XHANCE prescription increased 36% to $285 in 2024.
• The FDA approved XHANCE for the treatment of chronic rhinosinusitis without nasal polyps in March 2024.
• The company is required to conduct clinical trials of XHANCE in adolescent patients.
• The company is seeking partnerships to extend the commercialization of XHANCE into primary care.
• The company is transitioning a significant proportion of the XHANCE business from its historical preferred pharmacy network to a central intake pharmacy model (HUB).

Negatives

• OptiNose has identified conditions and events that raise substantial doubt about its ability to continue as a going concern.
• The company's continuation as a going concern is dependent on its ability to maintain compliance with financial covenants under the A&R Note Purchase Agreement, generate sufficient cash flows, and/or obtain additional capital.
• The company has incurred significant net losses since inception and anticipates that it will incur continued losses in the future.
• The company believes it is probable that it will not maintain compliance with the trailing twelve-month minimum consolidated XHANCE net sales and royalties thresholds for the entire one year period after the date these consolidated financial statements are issued.
• The company believes it is unlikely that it will be able to comply with the going concern covenant commencing with its financial statements for the year ending December 31, 2025.

Risks

• Failure to successfully commercialize XHANCE could materially adversely affect the business, financial condition, and results of operations.
• The commercial success of XHANCE depends upon its acceptance by multiple stakeholders, including physicians, patients, and third-party payors.
• If third-party payors do not reimburse patients for XHANCE or if reimbursement levels are set too low, the ability to successfully commercialize XHANCE will be harmed.
• The company relies on HUB and PPN partners for distribution of XHANCE in the U.S., and the failure of those HUB and PPN partners to distribute XHANCE effectively would adversely affect sales of XHANCE.
• The company may be unable to form and maintain relationships with pharmacies that participate in its Hub, PPN and patient affordability programs, which could adversely affect the commercialization of XHANCE and its operating results.
• If the FDA or other applicable regulatory authorities approve generic or similar products that compete with XHANCE, it could decrease expected sales of XHANCE.
• The company's relationships with physicians, patients, payors and pharmacies in the U.S. are subject to applicable anti-kickback, fraud and abuse laws and regulations.
• Delays in clinical trials are common and have many causes, and any delay could result in increased costs to the company and jeopardize or delay its ability to obtain regulatory approval and commence product sales, or its ability to maintain regulatory approval.
• If the company encounters difficulties in maintaining commercial manufacturing and supply agreements with its third-party manufacturers and suppliers of XHANCE or if it encounters issues with the performance of its contract manufacturers or suppliers, its ability to commercialize and manufacture XHANCE would be impaired.
• The price of the company's common stock may be volatile and you may lose all or part of your investment.
• Failure to complete the Merger could negatively affect the price of the company's common stock, as well as its future business and financial results.
• Expenses related to the proposed Merger are significant and will adversely affect the company's operating results.
• Uncertainties associated with the Merger may cause a loss of management and other key employees and disrupt the company's business relationships, which could adversely affect its business.
• The Merger Agreement limits the company's ability to pursue alternatives to the Merger and may discourage other companies from trying to acquire it for greater consideration than what Paratek has agreed to pay.

Future Outlook

The company is relaunching XHANCE to focus on the larger market opportunity created by the new indication and is seeking partnerships to extend the commercialization of XHANCE into primary care. The company anticipates that the Merger with Paratek will be consummated in the second or third quarter of 2025.

Industry Context

The treatment of chronic rhinosinusitis is a competitive market with various options including intranasal steroids, oral steroids, monoclonal antibodies, and surgical procedures. OptiNose aims to position XHANCE as a standard of care for patients dissatisfied with conventional INS treatments but before progressing to costly surgical interventions and monoclonal antibodies.

Comparison to Industry Standards

• The improvement with the 186and 372mcg doses of XHANCE was superior to the placebo EDS in both NAVIGATE I and NAVIGATE II.
• The magnitude of improvement associated with treatment with XHANCE was approximately 20 points.
• Although cross-trial comparisons have significant limitations and must be interpreted with caution, in a previous third-party study evaluating a large cohort (n=1468) of patients who were underwent sinus surgery, the degree of change on this outcome measure was approximately 18 points.

Stakeholder Impact

• Shareholders face uncertainty due to the going concern qualification and potential dilution from future equity issuances.
• Employees may experience job insecurity due to the company's financial situation and the pending merger.
• Customers and patients may be affected by potential disruptions in the supply and distribution of XHANCE.
• Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

• The company is relaunching XHANCE to focus on the larger market opportunity created by the new indication.
• The company is seeking partnerships to extend the commercialization of XHANCE into primary care.
• The company is transitioning a significant proportion of the XHANCE business from its historical preferred pharmacy network to a central intake pharmacy model (HUB).
• The company is required to conduct clinical trials of XHANCE in adolescent patients with chronic rhinosinusitis with and without nasal polyps.
• The company anticipates that the Merger with Paratek will be consummated in the second or third quarter of 2025.

Key Dates

Keywords

XHANCE, OptiNose, chronic rhinosinusitis, commercialization, net revenue, FDA approval, Merger, Paratek, financial results, going concern, A&R Note Purchase Agreement, clinical trials, pharmaceutical